Scarica l'app Stockscreener
13.81
0.36%
0.05
Dopo l'orario di chiusura:
13.83
0.02
+0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale - Streetwise Reports
Summit Therapeutics schedules Q2 2026 results, operational update call - Bitget
Kalshi to allow bets on clinical trials, FDA decisions - marketscreener.com
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026 - BioSpace
Press Release: Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026 - Moomoo
SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update - Stocktwits
Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal - Yahoo Finance
The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ridinilazole Sale And Royalty Deal - simplywall.st
Summit Therapeutics (SMMT) Partners with Biossil for Ridinilazole Sale - GuruFocus
Summit to sell antibiotic to Canada’s Biossil for up to $105M - MSN
Summit Therapeutics Inc. Signs Agreement to Sell Ridinilazole to Biossil, Inc - marketscreener.com
Summit Therapeutics sells ridinilazole to Biossil for $500k By Investing.com - Investing.com South Africa
Summit Therapeutics Sells Phase III Antibiotic Ridinilazole to Biossil in Milestone Deal - citybiz
Summit Therapeutics (SMMT) Sells Ridinilazole to Biossil for Up to $105M - GuruFocus
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc. - BioSpace
Price to earnings forward of Summit Therapeutics Inc – BMV:SMMT - TradingView
Summit Therapeutics sells ridinilazole to Biossil for $500k - Investing.com
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring an 87.99% Potential Upside in Biotechnology - DirectorsTalk Interviews
Why is SMMT stock tumbling today? - MSN
Why (SMMT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Summit Therapeutics (SMMT) Q1 2025 earnings summary - Quartr
Summit Therapeutics (SMMT) Jefferies London Healthcare Conference 2025 Summary - Quartr
Price to sales forward of Summit Therapeutics Inc. – NASDAQ:SMMT - TradingView
Enterprise value to EBITDA forward of Summit Therapeutics Inc. – NASDAQ:SMMT - TradingView
Price to book forward of Summit Therapeutics Inc. – NASDAQ:SMMT - TradingView
Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of Summit Therapeutics Inc. – NASDAQ:SMMT - TradingView
Summit Therapeutics Company Profile & Introduction - Moomoo
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring an 85% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
If You Invested $1,000 in Summit Therapeutics Inc (SMMT) - Stock Titan
Understanding Momentum Shifts in (SMMT) - Stock Traders Daily
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering? - Sahm
Summit Therapeutics Inc Actuals & Estimates (NASDAQ:SMMT) - TradingView
Summit Therapeutics Inc Actuals & Estimates (BMV:SMMT) - TradingView
SMMT Forecast — Price Target — Prediction for 2027 - TradingView
Why Is SMMT Stock Tumbling Today? - Stocktwits
Summit Therapeutics finance chief tops list of public CFO pay in 2025 - CFO.com
Bernstein raises Summit Therapeutics stock price target on trial outlook By Investing.com - Investing.com Australia
Bernstein raises Summit Therapeutics stock price target on trial outlook - Investing.com
Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing - Insider Monkey
Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet (NASDAQ:SMMT) - Seeking Alpha
Bernstein Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Raises Target Price to $9.8 - Moomoo
Summit Therapeutics (SMMT) Q4 2025 earnings summary - Quartr
5 Most Promising Healthcare Stocks According to Wall Street Analysts - Insider Monkey
SMMT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
0.80%
2.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):